Table 2.

Clinical events in 39/154 patients with hereditary hemorrhagic telangiectasia (HHT) and liver vascular malformations (VMs)

Patient	Agea(y)	Sex	Liver VMs stagea	HOCF	Atrial fibrillation	Supraventricular tachycardia	Portal hypert	Ascites	Encephalopathy	GI bleeding	Abdominal angina	Outcome
1	37	M	4			1	1			1	1b	Alive
2	62	F	2							1b		Alive
3	79	M	4	1b	1			1				Alive
4	61	F	4	1b	1			1				Dead
5	64	M	4				1			1b		Dead
6	79	M	4				1			1b		Alive
7	49	F	4				1			1b		Alive
8	64	F	4	1b								Alive
9	57	F	4	1b	1							Alive
10	56	F	2							1b		Alive
11	39	F	4				1	1				Alive
12	64	M	2							1b		Alive
13	62	M	1							1b		Alive
14	73	M	3	1b				1				Alive
15	22	F	4	1b	1		1					Alive
16	69	F	4	1b								Alive
17	48	F	4				1	1b				Dead
18	48	F	4	1b	1		1	1		1		Alive
19	36	F	4	1b	1			1				Alive
20	59	F	4	1b	1			1				Dead
21	69	F	3			1b						Alive
22	69	F	2						1b			Alive
23	74	F	4				1	1b				Dead
24	64	M	2				1	1		1b		Alive
25	31	M	3	1b				1				Alive
26	69	F	4				1		1	1b		Alive
27	70	F	4		1b		1					Alive
28	64	F	4	1b			1	1				Dead
29	38	M	3		1b
30	57	M	2							1b		Alive
31	49	M	2							1b		Alive
32	52	F	2		1b							Alive
33	58	M	3	1b	1							Alive
34	82	F	4	1b	1							Dead
35	82	F	4				1			1b		Dead
36	56	M	3				1	1b				Alive
37	62	F	3				1			1b		Alive
38	52	F	3			1b						Alive
39	39	F	2			1b						Alive
Totalc				14 (9)	12 (8)	4 (3)	16 (10)	13 (8)	2 (1)	15 (10)	1 (1)	Alive

HOCF high-output cardiac failure

The first 13 patients had symptoms at enrolment. Patient 37 had coexistent HCV-related compensated cirrhosis. Patient 18 had mild arterial hypertension

^aAt diagnosis

^bThe clinically dominant feature, and which was the death cause in cases with adverse outcome

^cPercentages in brackets (number of complications/154 pts) are rounded to the next integer for decimal points >0.5